Table 2

Irinotecan/temozolomide treatment for recurrent Ewing sarcoma: comparison of 5 day and 10 day schedules of administration

|  |  |  |  |
| --- | --- | --- | --- |
| **Irinotecan dose schedule** | | | |
| **Daily x 5 days x 2 weeks (10 doses)** | | **Daily x 5 days x 1 week (5 doses)** | |
| Patients | Objective responses | Patients | Objective responses |
| 94 | 48 (51%) | 218 | 65 (30%) |